SPRUCE BIOSCIENCES, INC.
SPRB evidence brief
What we can confirm
- BioSniper Score:
- 6.9 / 10
- Market Cap:
- $154.3M
- Next Catalyst:
- Phase3_Start · Dec 1, 2026
What it means
What to watch
Prepared research question
What matters most for SPRB—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SPRB
SPRUCE BIOSCIENCES, INC. (SPRB) is a late-stage biopharmaceutical company developing therapies for neurological disorders, with its lead candidate TA-ERT for Sanfilippo Syndrome Type B approaching a BLA submission in Q4 2026.
Key risk: No approved products or revenue
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 8 clinical trials · 1 catalyst for SPRUCE BIOSCIENCES, INC..
SPRUCE BIOSCIENCES, INC. (SPRB) is a late-stage biopharmaceutical company developing therapies for neurological disorders, with its lead candidate TA-ERT for Sanfilippo Syndrome Type B approaching a BLA submission in Q4 2026.
- Cash & equivalents of $96.3M as of 2026-06-30 [sec].
- Net income of -$16.2M as of 2026-06-30 [sec].
- Shareholders' equity of $83.7M and total debt of $16.6M as of 2026-06-30 [sec].
- Lead candidate TA-ERT (tralesinidase alfa) received breakthrough therapy designation from the FDA in October 2025 for Sanfilippo Syndrome Type B [sec_mda · as of 2026-08-12].
- BLA submission for TA-ERT is on track for Q4 2026, supported by positive pre-BLA meetings with the FDA [news · published 2026-08-24].
What works
- TA-ERT has received multiple FDA designations (Breakthrough Therapy, Rare Pediatric Disease, Fast Track, Orphan Drug) and EU Orphan Drug Designation, indicating regulatory support [sec_mda · as of 2026-08-12].
- The company has completed positive pre-BLA meetings with the FDA, de-risking the BLA submission process for TA-ERT [news · published 2026-08-24].
- Cash position of $96.3M as of 2026-06-30 is expected to fund operations for at least 12 months, providing near-term financial runway [sec_mda · as of 2026-08-12].
What to weigh
- The company has no products approved for commercial sale and has not generated any product revenue to date [sec_mda · as of 2026-08-12].
- Substantial additional capital will be needed to develop and launch TA-ERT and fund operations, with no guarantee of availability on acceptable terms [sec_mda · as of 2026-05-13].
- Research and development expenses are expected to increase significantly as the company pursues regulatory approval and builds a commercial organization [sec_mda · as of 2026-08-12].
From the filings
Quoted directly from source documents.
TA-ERT received breakthrough therapy designation from the FDA in October 2025.
“In October 2025, TA-ERT received breakthrough therapy designation from the U.S. Food and Drug Administration ("FDA") for the treatment of Sanfilippo Syndrome Type B.”
SEC MD&A · August 12, 2026
BLA submission for TA-ERT is on track for Q4 2026.
“We anticipate submitting a biologics license application of TA-ERT for the treatment of Sanfilippo Syndrome Type B in the fourth quarter of 2026.”
SEC MD&A · August 12, 2026
The company has no approved products and no product revenue.
“We have no products approved for commercial sale and have not generated any product revenue to date”
SEC MD&A · August 12, 2026
Catalyst timeline
- 2026-12-01 · Phase3_Start — A Phase 3 study evaluating tralesinidase alfa for MPS IIIB is scheduled to start, which will be a key milestone for the TA-ERT program.
Risks & what to watch (3)›
Key risks
- No approved products or revenue — Company has no products approved for commercial sale and has not generated any product revenue to date [sec_mda · as of 2026-08-12].
- Need for substantial additional capital — Company anticipates needing to raise substantial additional capital, with no guarantee of availability on acceptable terms [sec_mda · as of 2026-05-13].
- Increasing R&D expenses — Research and development expenses are expected to increase significantly as the company pursues regulatory approval and commercialization [sec_mda · as of 2026-08-12].
What to watch
- BLA submission for TA-ERT in Q4 2026 and subsequent FDA review [news · published 2026-08-24].
- Cash runway and any additional financing rounds, as cash of $96.3M as of 2026-06-30 is expected to fund operations for at least 12 months [sec_mda · as of 2026-08-12].
- Progress of preclinical candidates SPR202 (CAH) and SPR204 (post-bariatric hypoglycemia) [pipeline].
- Phase 2 results for tildacerfont in CAH and polycystic ovary syndrome [pipeline].
Sources: Catalysts · News · Pipeline · SEC MD&A · Generated October 6, 2026 · How we verify sources →
Run SPRUCE BIOSCIENCES, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available SPRUCE BIOSCIENCES, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 0.23 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
1 upcoming, next in ~48d
No insider transactions in the last 180 days
Catalysts
Regulatory
Financials
Short Interest
as of Apr 28, 2026- % of float
- 13.4%
- Days to cover
- 3.4
- Shares short
- 180,537
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SPRB short interestGovernance
Frequently asked questions
What is the AI investment thesis for SPRUCE BIOSCIENCES, INC.?
SPRUCE BIOSCIENCES, INC. (SPRB) is a late-stage biopharmaceutical company developing therapies for neurological disorders, with its lead candidate TA-ERT for Sanfilippo Syndrome Type B approaching a BLA submission in Q4 2026.
What is SPRUCE BIOSCIENCES, INC.'s next catalyst?
SPRUCE BIOSCIENCES, INC.'s next tracked catalyst is a Phase3_Start event — "Phase3_Start: A Phase 3, Randomized, Single-blind, Parallel Group, Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of Intracerebroventricular Tralesinidase Alfa Treatment Compared to Standard of Care in Mucopolysaccharidosis Type IIIB (MPS IIIB, Sanfilippo Syndrome Type B)" — expected December 1, 2026.
Who is the CEO of SPRUCE BIOSCIENCES, INC.?
Dr. Javier Szwarcberg M.D., M.P.H. is the chief executive officer of SPRUCE BIOSCIENCES, INC. (SPRB).
Where is SPRUCE BIOSCIENCES, INC. headquartered?
SPRUCE BIOSCIENCES, INC. (SPRB) is headquartered in South San Francisco, CA, United States.
What therapeutic areas does SPRUCE BIOSCIENCES, INC. focus on?
SPRUCE BIOSCIENCES, INC. develops therapies across Oncology, Rare Disease, Nephrology, Endocrinology, Reproductive.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.